---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-073998"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-07-01T12:05:36+00:00"
generated_at: "2026-07-01T12:11:07.904023+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics granted U.S. patent for stenoparib DRP companion diagnostic through April 2042

## Summary
- USPTO granted key U.S. patent covering stenoparib-specific Drug Response Predictor (DRP) companion diagnostic.
- Patent term extends into April 2042, providing long-term exclusivity for stenoparib when used with the DRP test.
- Patent covers methods to predict clinical benefit from stenoparib based on tumor gene-expression profiles and patient selection.
- Allarity also has patent protection for stenoparib DRP in Europe and Australia into 2039.

## SEC filing metadata
- accession: 0001213900-26-073998
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-07-01T12:05:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026073998/0001213900-26-073998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026073998/ea0296615-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-073998
- JSON: https://secwatch.observer/filing/0001213900-26-073998.json
- Plain text: https://secwatch.observer/filing/0001213900-26-073998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.